Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Challenges in the Correct Assessment of a Case of Aggressive Thyroid Carcinoma with Synchronous Breast Cancer: A Case Report and Review of the Literature of Essential Role of Radiopharmaceuticals

Author(s): Andra Piciu, Alexandru Mester*, George Rusu and Doina Piciu*

Volume 14, Issue 2, 2021

Published on: 28 September, 2020

Page: [85 - 91] Pages: 7

DOI: 10.2174/1874471013666200928105151

Price: $65

Abstract

Thyroid carcinoma represents a complex pathology that can still be considered a medical challenge, despite having a better prognosis and life expectancy than most other neoplasms; also the scenario of multiple malignancies involving thyroid cancer is nowadays a common reality.

Materials and methods: We reviewed the literature regarding the aggressive presentation of synchronous thyroid and breast cancer. In the current paper, we report the case of a 59 years-old woman, diagnosed with invasive ductal breast carcinoma and papillary thyroid carcinoma, presenting a natural history of both aggressive synchronous tumors. At the moment of hospitalization, the diagnosis was breast carcinoma with multiple secondary lesions, suggestive of lung and bone metastases, and nodular goiter.

Results: Searching the literature in PUBMED with the terms “thyroid carcinoma and synchronous breast carcinoma, we found 86 studies; introducing the term “aggressive,” the result included 4 studies, among which, none showed to be relevant to the terms aggressive and synchronous. A similar search was done in SCOPUS finding 92 documents and after introducing the term aggressive, the number of papers was 8, none including the literature on synchronous aggressive metastatic thyroid and breast carcinoma. A majority of imaging diagnostic tools were used in this particular medical case in order to ensure the best potential outcome. The final diagnosis was papillary thyroid carcinoma with lung and unusual multiple bone metastases and synchronous invasive ductal breast carcinoma with subcutaneous metastases.

Conclusion: The case illustrates the challenges in the correct assessment of oncologic patients, despite the advances in medical imaging and technologies and underlines the essential role of nuclear medicine procedures in the diagnostic and therapy protocols.

Keywords: Thyroid carcinoma, breast carcinoma, synchronous, aggressive, diagnostic algorithm, radiopharmaceuticals.

« Previous
Graphical Abstract

[1]
Institute, N.N.C. Cancer Facts & Figures 2020. CA Cancer J. Clin., 2020, 1-76.
[2]
Brito, J.P.; Al Nofal, A.; Montori, V.M.; Hay, I.D.; Morris, J.C. The Impact of Subclinical Disease and Mechanism of Detection on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Olmsted County, Minnesota During 1935 Through 2012. Thyroid, 2015, 25(9), 999-1007.
[http://dx.doi.org/10.1089/thy.2014.0594] [PMID: 26103159]
[3]
Wells, S.A., Jr Progress in endocrine neoplasia. Clin. Cancer Res., 2016, 22(20), 4981-4988.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-0384] [PMID: 27742784]
[4]
Piciu, D.; Piciu, A.; Irimie, A. Papillary thyroid microcarcinoma and ectopic papillary thyroid carcinoma in mediastinum: a case report. Clin. Nucl. Med., 2012, 37(2), 214-215.
[http://dx.doi.org/10.1097/RLU.0b013e318238f334] [PMID: 22228358]
[5]
Piciu, D. Thyroid cancer incidence 25 years after Chernobyl, in a Romanian cancer center: is it a public health problem? Curr. Radiopharm., 2013, 6(4), 249-252.
[http://dx.doi.org/10.2174/1874471006666140109114218] [PMID: 24410626]
[6]
Aboelnaga, E.M.; Ahmed, R.A. Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution. Cancer Biol. Med., 2015, 12(1), 53-59.
[PMID: 25859412]
[7]
Wenig, B.M.; Thompson, L.D.R.; Adair, C.F.; Shmookler, B.; Heffess, C.S. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases. Cancer, 1998, 82(4), 740-753.
[http://dx.doi.org/10.1002/(SICI)1097-0142(19980215)82:4<740::AID-CNCR18>3.0.CO;2-Y] [PMID: 9477108]
[8]
Chen, J.H.; Faquin, W.C.; Lloyd, R.V.; Nosé, V. Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. Mod. Pathol., 2011, 24(5), 739-749.
[http://dx.doi.org/10.1038/modpathol.2011.2] [PMID: 21358618]
[9]
Motosugi, U.; Murata, S.; Nagata, K.; Yasuda, M.; Shimizu, M. Thyroid papillary carcinoma with micropapillary and hobnail growth pattern: a histological variant with intermediate malignancy? Thyroid, 2009, 19(5), 535-537.
[http://dx.doi.org/10.1089/thy.2008.0271] [PMID: 19348583]
[10]
Asioli, S.; Maletta, F.; Pagni, F.; Pacchioni, D.; Vanzati, A.; Mariani, S.; Palestini, N.; Lloyd, R.V.; Sapino, A. Cytomorphologic and molecular features of hobnail variant of papillary thyroid carcinoma: case series and literature review. Diagn. Cytopathol., 2014, 42(1), 78-84.
[http://dx.doi.org/10.1002/dc.23028] [PMID: 23913779]
[11]
Wang, X.; Cheng, W.; Liu, C.; Li, J. Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology. Oncotarget, 2016, 7(26), 40792-40799.
[http://dx.doi.org/10.18632/oncotarget.8215] [PMID: 27008708]
[12]
Ahmadi, S.; Stang, M.; Jiang, X.S.; Sosa, J.A. Hürthle cell carcinoma: current perspectives. OncoTargets Ther., 2016, 9, 6873-6884.
[http://dx.doi.org/10.2147/OTT.S119980] [PMID: 27853381]
[13]
Falvo, L.; Catania, A.; D’Andrea, V.; Marzullo, A.; Giustiniani, M.C.; De Antoni, E. Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma. Ann. Surg., 2005, 241(4), 640-646.
[http://dx.doi.org/10.1097/01.sla.0000157317.60536.08] [PMID: 15798466]
[14]
Cao, J.; Hu, J.L.; Chen, C.; Wang, Q.L.; Fang, X.H.; Zhang, Y.; Ge, M.H. Vascular invasion is an independent prognostic factor for distant recurrence-free survival in papillary thyroid carcinoma: a matched-case comparative study. J. Clin. Pathol., 2016, 69(10), 872-877.
[http://dx.doi.org/10.1136/jclinpath-2015-203547] [PMID: 27010434]
[15]
Vuong, H.G.; Kondo, T.; Duong, U.N.P.; Pham, T.Q.; Oishi, N.; Mochizuki, K.; Nakazawa, T.; Hassell, L.; Katoh, R. Prognostic impact of vascular invasion in differentiated thyroid carcinoma: a systematic review and meta-analysis. Eur. J. Endocrinol., 2017, 177(2), 207-216.
[http://dx.doi.org/10.1530/EJE-17-0260] [PMID: 28566444]
[16]
Tessler, F.N.; Middleton, W.D.; Grant, E.G.; Hoang, J.K.; Berland, L.L.; Teefey, S.A.; Cronan, J.J.; Beland, M.D.; Desser, T.S.; Frates, M.C.; Hammers, L.W.; Hamper, U.M.; Langer, J.E.; Reading, C.C.; Scoutt, L.M.; Stavros, A.T. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J. Am. Coll. Radiol., 2017, 14(5), 587-595.
[http://dx.doi.org/10.1016/j.jacr.2017.01.046] [PMID: 28372962]
[17]
Cibas, E.S.; Ali, S.Z. NCI Thyroid FNA State of the Science Conference. The Bethesda system for reporting thyroid cytopathology. Am. J. Clin. Pathol., 2009, 132(5), 658-665.
[http://dx.doi.org/10.1309/AJCPPHLWMI3JV4LA] [PMID: 19846805]
[18]
Tuttle, R.M.; Haugen, B.; Perrier, N.D. The Updated AJCC/TNM Staging System for Differentiated and Anaplastic Thyroid Cancer, 8th edition:What changed and why? Thyroid, 2017, 27(6), 751-6.
[19]
Haugen, BR; Alexander, EK; Bible, KC; Doherty, GM; Mandel, SJ; Nikiforov, YE American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer Thyroid Am Thyroid Assoc, 2016, 26(1)
[20]
Piciu, D. Diagnosis and Treatment Guidlines in Thyroid Carcinoma. American and European Consensus, adapted to Romania Acta Endocrinol, 2007, 3(1), 103-15.http://www.acta-endo.ro/actamedica/abstract.php?doi=2007.103
[21]
Piccardo, A.; Arecco, F.; Puntoni, M.; Foppiani, L.; Cabria, M.; Corvisieri, S.; Arlandini, A.; Altrinetti, V.; Bandelloni, R.; Orlandi, F. Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival. Clin. Nucl. Med., 2013, 38(1), 18-24.
[http://dx.doi.org/10.1097/RLU.0b013e318266d4d8] [PMID: 23242039]
[22]
Piciu, D.; Irimie, A.; Kontogeorgos, G.; Piciu, A.; Buiga, R. Highly aggressive pathology of non-functional parathyroid carcinoma. Orphanet J. Rare Dis., 2013, 8(1), 115. [Internet].
[http://dx.doi.org/10.1186/1750-1172-8-115] [PMID: 23915575]
[23]
Gomes-Lima, C.J.; Wu, D.; Rao, S.N.; Punukollu, S.; Hritani, R.; Zeymo, A.; Deeb, H.; Mete, M.; Aulisi, E.F.; Van Nostrand, D.; Jonklaas, J.; Wartofsky, L.; Burman, K.D. Brain Metastases From Differentiated Thyroid Carcinoma: Prevalence, Current Therapies, and Outcomes. J. Endocr. Soc., 2018, 3(2), 359-371.
[http://dx.doi.org/10.1210/js.2018-00241] [PMID: 30706042]
[24]
Datz, F.L. Cerebral edema following iodine-131 therapy for thyroid carcinoma metastatic to the brain. J. Nucl. Med., 1986, 27(5), 637-640.
[PMID: 3712081]
[25]
Khoo, A.C.H.; Fong, L.Y.; Hamzah, F. A Review of TENIS Syndrome in Hospital Pulau Pinang. Indian J. Nucl. Med., 2018, 33(4), 284-289.
[http://dx.doi.org/10.4103/ijnm.IJNM_65_18] [PMID: 30386048]
[26]
Larg, M.I.; Barbus, E.; Gabora, K.; Pestean, C.; Cheptea, M.; Piciu, D. 18F-FDG PET/CT IN DIFFERENTIATED THYROID CARCINOMA Acta Endocrinol (Bucharest, Rom 2005), 2019, 15(2), 203-208.https://europepmc.org/articles/PMC6711650
[27]
Warren, S.; Ehrenreich, T. Multiple Primary Malignant Tumors and Susceptibility to Cancer. Cancer Res., 1944, 4(9), 554-570.
[28]
Zhai, C.; Cai, Y.; Lou, F.; Liu, Z.; Xie, J.; Zhou, X.; Wang, Z.; Fang, Y.; Pan, H.; Han, W. Multiple Primary Malignant Tumors - A Clinical Analysis of 15,321 Patients with Malignancies at a Single Center in China. J. Cancer, 2018, 9(16), 2795-2801.
[http://dx.doi.org/10.7150/jca.25482] [PMID: 30123347]
[29]
Badan, M-I.; Piciu, D. Triple Metachronous Malignancies with Thyroid Involvement: A Brief Overview of Five Case Reports over 20 Years of Institutional Experience Diagnostics (Basel, Switzerland)., 2020; 10, p. (3)168.
[30]
Piciu, D.; Pestean, C.; Barbus, E.; Larg, M.I.; Piciu, A. Second malignancies in patients with differentiated thyroid carcinoma treated with low and medium activities of radioactive I-131. Clujul Med., 2016, 89(3), 384-389.
[PMID: 27547058]
[31]
Li, F.; Zhong, W-Z.; Niu, F-Y.; Zhao, N.; Yang, J-J.; Yan, H-H.; Wu, Y.L. Multiple primary malignancies involving lung cancer. BMC Cancer, 2015, 15, 696.
[http://dx.doi.org/10.1186/s12885-015-1733-8] [PMID: 26466785]
[32]
Gradishar, W.J.; Anderson, B.O.; Balassanian, R.; Blair, S.L.; Burstein, H.J.; Cyr, A.; Elias, A.D.; Farrar, W.B.; Forero, A.; Giordano, S.H.; Goetz, M.P.; Goldstein, L.J.; Isakoff, S.J.; Lyons, J.; Marcom, P.K.; Mayer, I.A.; McCormick, B.; Moran, M.S.; O’Regan, R.M.; Patel, S.A.; Pierce, L.J.; Reed, E.C.; Salerno, K.E.; Schwartzberg, L.S.; Sitapati, A.; Smith, K.L.; Smith, M.L.; Soliman, H.; Somlo, G.; Telli, M.L.; Ward, J.H.; Kumar, R.; Shead, D.A. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw., 2018, 16(3), 310-320.
[http://dx.doi.org/10.6004/jnccn.2018.0012] [PMID: 29523670]
[33]
Krathen, R.A.; Orengo, I.F.; Rosen, T. Cutaneous metastasis: a meta-analysis of data. South. Med. J., 2003, 96(2), 164-167.
[http://dx.doi.org/10.1097/01.SMJ.0000053676.73249.E5] [PMID: 12630642]
[34]
Romaniuk Cyrillic capital A, Lyndin M, Smiyanov V, Sikora V, Rieznik A, Kuzenko Y, et al. Primary multiple tumor with affection of the thyroid gland, uterus, urinary bladder, mammary gland and other organs Pathol Res Pract, 2017, 213(5), 574-9.
[35]
Hsu, C-H.; Huang, C-L.; Hsu, Y-H.; Iqbal, U.; Nguyen, P-A.; Jian, W-S. Co-occurrence of second primary malignancy in patients with thyroid cancer. QJM, 2014, 107(8), 643-648.
[http://dx.doi.org/10.1093/qjmed/hcu051] [PMID: 24623860]
[36]
Riedl, C.C.; Slobod, E.; Jochelson, M.; Morrow, M.; Goldman, D.A.; Gonen, M.; Weber, W.A.; Ulaner, G.A. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J. Nucl. Med., 2014, 55(10), 1578-1583.
[http://dx.doi.org/10.2967/jnumed.114.143297] [PMID: 25214641]
[37]
Okere, P.C.N.; Olusina, D.B.; Shamim, S.A.; Shandra, V.; Tushar, M.; Sellam, K.; Bal, C. Pattern of second primary malignancies in thyroid cancer patients. Niger. J. Clin. Pract., 2013, 16(1), 96-99.
[http://dx.doi.org/10.4103/1119-3077.106775] [PMID: 23377480]
[38]
Silberstein, E.B.; Alavi, A.; Balon, H.R.; Clarke, S.E.M.; Divgi, C.; Gelfand, M.J.; Goldsmith, S.J.; Jadvar, H.; Marcus, C.S.; Martin, W.H.; Parker, J.A.; Royal, H.D.; Sarkar, S.D.; Stabin, M.; Waxman, A.D. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J. Nucl. Med., 2012, 53(10), 1633-1651.
[http://dx.doi.org/10.2967/jnumed.112.105148] [PMID: 22787108]
[39]
Muntean, V.; Domsa, I.; Zolog, A.; Piciu, D.; Fabian, O.; Bosu, R.; Simescu, R.; Petre, G.; Muntean, M.V. Incidental papillary thyroid microcarcinoma: is completion surgery required? Chirurgia (Bucur.), 2013, 108(4), 490-497.
[PMID: 23958091]
[40]
Kim, J.H.; Kang, I.; Nam, S.; Park, H.S.; Park, S.; Jeong, J.J. Comparison of characteristics in patients with both thyroid and breast cancer: Based on order of incidence. Korean J. Clin. Oncol., 2017, 13(1), 1-9. [Internet].
[http://dx.doi.org/10.14216/kjco.17001]

Rights & Permissions Print Cite
Article Metrics
19
© 2024 Bentham Science Publishers | Privacy Policy